000			nab a22 7a 4500
999			_c17261 _d17261
003			PC17261
005			20230224135945.0
008			230224b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9286 _aCaro Espada, Paula Jara _eNefrología
100			_92028 _aGutiérrez Solís, Elena _eNefrología
100			_91488 _aPraga Terente, Manuel _eNefrología
245	0	0	_aPredictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. _h[artículo]
260			_bNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, _c2015
300			_a30(3):467-74.
500			_aFormato Vancouver: Caro J, Gutiérrez Solís E, Rojas Rivera J, Agraz I, Ramos N, Rabasco C et al; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant. 2015 Mar;30(3):467-74.
501			_aPMID: 25274748
504			_aContiene 26 referencias
520			_aBackground: Although tacrolimus is recommended by KDIGO Clinical Practice Guideline for Glomerulonephritis for the treatment of idiopathic membranous nephropathy (MN), little is known about factors that influence response and relapse of the disease after tacrolimus therapy. Methods: Multicentre study that collected 122 MN patients with nephrotic syndrome and stable renal function treated with tacrolimus. Duration of treatment was 17.6 ± 7.2 months, including a full-dose and a tapering period. Results: The percentage of remission was 60, 78 and 84% after 6, 12 and 18 months of treatment, respectively. The amount of proteinuria at baseline significantly predicted remission, the lower the baseline proteinuria the higher the probability of remission. Only 10 patients (8%) received concomitantly corticosteroids, and their rate of remission was similar (80% at 18 months). Among responders, 42% achieved complete remission (CR) and 58% partial remission (PR). Almost half (44%) of the responder patients relapsed. The amount of proteinuria at the onset of tacrolimus tapering was significantly higher in relapsing patients. By multivariable analysis, the presence of a PR versus CR at the onset of tacrolimus tapering and a shorter duration of the tapering period significantly predicted relapses. Tolerance was good and the number of adverse events low. Conclusions: Tacrolimus monotherapy is an effective and safe option for the treatment of MN with stable renal function. Relapses are frequent in patients with PR and can be partially prevented by a longer tapering period.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17261.pdf _ySolicitar documento
942			_2ddc _cART _n0